Trial Profile

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 137173A (Primary)
Indications Herpes zoster
Focus Pharmacodynamics

Most Recent Events

16 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Apr 2021.
03 Jun 2020 Results assessing the safety and immunogenicity of subunit recombinant herpes zoster vaccine (RZV) in lung transplant recipients (LTR) who are known to be at high risk for herpes zoster reactivation compared to other organ transplant recipients, were presented at the 2020 American Transplant Congress.
24 Sep 2019 Planned End Date changed from 5 Mar 2020 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com